Dan Liu
Direttore/Membro del Consiglio presso JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Yi Min Hua | M | 42 | 15 anni | |
Jiong Lan | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | 7 anni |
Ming De Xia | M | - |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | 4 anni |
Zuo Jun Xu | M | 53 | 2 anni | |
Juan Du | F | 42 | 4 anni | |
Hai Ge Shen | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Qing Song Sheng | M | - |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | - |
Feng Xiao | M | 61 | 26 anni | |
Yin Hua Zhu | M | 40 | 13 anni | |
Tao Wang | M | 39 | 1 anni | |
Yu Wang | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Bo Yu | M | 54 | 4 anni | |
Guo Ping Hua | M | 70 | 15 anni | |
Chong Bo Xu | M | 41 | 2 anni | |
Li Liu | M | 45 | 2 anni | |
Bin Qing Xiao | M | 45 | 4 anni | |
Qiang Lü | M | 39 |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | 7 anni |
Wei Guo Ma | M | 55 | 26 anni | |
Jing Hu | F | 40 | 2 anni | |
Yu Fa Wei | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Wei Zhang | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Bing Bai | M | 42 | 2 anni | |
Bin Li | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Hui Wang | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Yiou Wang | M | 40 | 1 anni | |
Jing Jiang | M | - |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | - |
Gao Guang Song | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Tao Wen | M | 45 | 4 anni | |
Yun Feng | M | - |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | - |
Zeng Jiao Sui | M | - |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | - |
De Rong Leng | M | 61 | 1 anni | |
Qing Zhong Tan | M | - |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | - |
Lun Li | M | 48 | 6 anni | |
Li Zhong Xu | M | 51 | 5 anni | |
Yu Ping Ye | F | 34 | 7 anni | |
Zhao Qian Wang | M | 37 | 6 anni | |
Ai Min Tang | M | - |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Yi Zhou | M | 44 |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | - |
Min Min Yang | M | 52 | 1 anni | |
Xue Liu | F | 29 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Ling Wu Zeng | M | 34 | - | |
Li Xin Yu | F | 59 | - | |
Suo Qiu | F | 62 | - | |
Yu Chen | M | 43 | 3 anni | |
Li Jian Liu | M | 49 | - | |
Xing Bo Gu | M | 35 | 3 anni | |
Xiao Shan Jiao | M | 49 | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Cina | 47 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Dan Liu
- Contatti personali